Display options
Cite
Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020;34(3):e13794doi: 10.1111/ctr.13794.
Lee, F., Nair, V., & Chih, S. (2020). Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clinical transplantation, 34(3), e13794. https://doi.org/10.1111/ctr.13794
Lee, Felicity, et al. "Cardiac allograft vasculopathy: Insights on pathogenesis and therapy." Clinical transplantation vol. 34,3 (2020): e13794. doi: https://doi.org/10.1111/ctr.13794
Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: Insights on pathogenesis and therapy. Clin Transplant. 2020 Mar;34(3):e13794. doi: 10.1111/ctr.13794. Epub 2020 Feb 11. PMID: 31991002.
Copy Download .nbib Format: NLM
Share it on

Clin Transplant. 2020 Mar;34(3):e13794. doi: 10.1111/ctr.13794. Epub 2020 Feb 11.

Cardiac allograft vasculopathy: Insights on pathogenesis and therapy.

Clinical transplantation

Felicity Lee, Vidhya Nair, Sharon Chih

Affiliations

  1. Heart Failure and Transplantation, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
  2. Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada.

PMID: 31991002 DOI: 10.1111/ctr.13794

Abstract

Cardiac allograft vasculopathy (CAV) is a unique accelerated form of coronary vascular disease affecting heart transplant recipients. This complication is a significant contributor to medium- to long-term post-transplant morbidity and mortality. There is a high prevalence of CAV with approximately one in three patients developing CAV by 5 years post-transplant. Morphologically, CAV is characterized by concentric coronary intimal hyperplasia in both the epicardial arteries and intramural microvasculature. Although several immune and non-immune factors have been identified, their precise pathogenic mechanisms, interactions, and relative importance in the development of CAV are not well defined. The advent of improved imaging surveillance modalities has resulted in earlier detection during the disease process. However, overall management of CAV remains challenging due to paucity of treatment. This review aims to discuss key concepts on the pathogenesis of CAV and current management strategies, focusing on the use of mammalian target of rapamycin inhibitors.

© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Keywords: cardiac allograft vasculopathy; heart transplant; mammalian target of rapamycin inhibitors

References

  1. Khush KK, Cherikh WS, Chambers DC, et al. The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report-2018; Focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018;37(10):1155-1168. - PubMed
  2. Tremblay-Gravel M, Racine N, de Denus S, et al. Changes in outcomes of cardiac allograft vasculopathy over 30 years following heart transplantation. JACC Heart Fail. 2017;5(12):891-901. - PubMed
  3. Langstraat M, Musters KJS, Manintveld O, Masetti M, Potena L. Coronary artery disease in heart transplantation: new concepts for an old disease. Transpl Int. 2018;31(8):787-827. - PubMed
  4. Lu W-H, Palatnik K, Fishbein GA, et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: A pathologic study of 64 allograft hearts. J Heart Lung Transplant. 2011;30:1044-1050. - PubMed
  5. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801-815. - PubMed
  6. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant. 2001;1(2):97-102. - PubMed
  7. Arora S, Gullestad L. The challenge of allograft vasculopathy in cardiac transplantation. Curr Opin Organ Transplant. 2014;19(5):508-514. - PubMed
  8. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 2008;117(16):2131-2141. - PubMed
  9. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180(4):2357-2366. - PubMed
  10. Loupy A, Toquet C, Rouvier P, et al. Late failing heart allografts: Pathology of cardiac allograft vasculopathy and assoiation with antibody mediated rejection. Am J Transplant. 2016;16(1):111-120. - PubMed
  11. Huibers MMH, Gareau AJ, Beerthuijzen JMT, et al. Donor-specific antibodies are produced locally in ectopic lymphoid structures in cardiac allografts. Am J Transplant. 2017;17(1):246-254. - PubMed
  12. Hiemann NE, Meyer R, Wellnhofer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation. 2012;94(9):919-924. - PubMed
  13. Kransdorf EP, Loghmanpour NA, Kanwar MK, Temkit MH, Stehlik J. Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods. Clin Transplant. 2017;31(4):e12925. - PubMed
  14. Mehra MR, Uber PA, Ventura HO, Scott RL, Park MH. The impact of mode of donor brain death on cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol. 2004;43(5):806-810. - PubMed
  15. Yamani MH, Starling RC, Cook DJ, et al. Donor spontaneous intracerebral hemorrhage is associated with systemic activation of matrix metalloproteinase-2 and matrix metalloproteinase-9 and subsequent development of coronary vasculopathy in the heart transplant recipient. Circulation. 2003;108:1724-1728. - PubMed
  16. Nikolova AP, Kobashigawa JA. Cardiac allograft vasculopathy-the enduring enemy of cardiac transplantation. Transplantation. 2019;103:1338-1448. - PubMed
  17. Delgado JF, Reyne AG, de Dios S, et al. Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant. 2015;34:1112-1119. - PubMed
  18. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation. 2009;119(24):3133-3141. - PubMed
  19. Weis M, Kledal TN, Lin KY, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation. 2004;109(4):500-505. - PubMed
  20. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol. 2009;19(1):47-56. - PubMed
  21. Potena L, Holweg CTJ, Vana ML, et al. Frequent occult infection with cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis. J Clin Microbiol. 2007;45(6):1804-1810. - PubMed
  22. Chih S, Chong AY, Mielniczuk LM, Bhatt DL, Beanlands RSB. Allograft Vasculopathy The Achilles’ Heel of Heart Transplantation. J Am Coll Cardiol. 2016;68(1):80-91. - PubMed
  23. Olymbios M, Kwiecinski J, Berma DS, Kobashigawa JA. Imaging in heart transplant patients. JACC Cardiovasc Imaging. 2018;11(10):1514-1530. - PubMed
  24. Erbel C, Mukhammadaminova N, Gleissner CA, et al. Myocardial perfusion reserve and strain-encoded CMR for evaluation of cardiac allograft microvasculopathy. JACC Cardiovasc Imaging. 2016;9(3):255-266. - PubMed
  25. Chih S, Chong AY, Erthal F, et al. PET assessment of epicardial intimal disease and microvascular dysfunction in cardiac allograft vasculopathy. J Am Coll Cardiol. 2018;71(13):1444-1456. - PubMed
  26. Wever-Pinzon O, Romero J, Kelesidis I, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63(19):1992-2004. - PubMed
  27. Miller CA, Sarma J, Naish JH, et al. Multiparametric cardiovascular magnetic resonance assessment of cardiac allograft vasculopathy. J Am Coll Cardiol. 2014;63(8):799-808. - PubMed
  28. Costanzo MR, Costanzo MR, Dipchand A, et al. The international society of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956. - PubMed
  29. Chirakarnjanakorn S, Starling RC, Popovic ZB, Griffin BP, Desai MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: Diagnostic accuracy and predictors of outcomes. J Heart Lung Transplant. 2015;34(5):710-717. - PubMed
  30. Bravo PE, Bergmark BA, Vita T, et al. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. Eur Heart J. 2018;39:316-323. - PubMed
  31. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. ISHLT consensus statement international society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29(7):717-727. - PubMed
  32. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17(8):744-753. - PubMed
  33. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients outcomes after five years. J Am Coll Cardiol. 2005;45(9):1532-1537. - PubMed
  34. Potena L, Masetti M, Sabatino M, et al. Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. J Heart Lung Transplant. 2015;34(9):1146-1153. - PubMed
  35. Cassar A, Matsuo Y, Herrmann J, et al. Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography. Eur Heart J. 2013;34:2610-2617. - PubMed
  36. Clemmensen TS, Holm NR, Eiskjaer H, et al. Layered fibrotic plaques are the predominant component in cardiac allograft vasculopathy: systematic findings and risk stratification by OCT. JACC Cardiovasc Imaging. 2017;10(7):773-784. - PubMed
  37. Vallakati A, Reddy S, Dunlap ME, Taylor DO. Impact of statin use after heart transplantation. Circ Heart Fail. 2016;9(10):e003265. - PubMed
  38. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96(5):1398-1402. - PubMed
  39. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107(1):93-97. - PubMed
  40. See VY, DeNofrio D, Goldberg L, et al. Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol. 2003;92(1):11-15. - PubMed
  41. O'Rourke B, Barbir M, Mitchell AG, Yacoub MH, Banner NR. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study. Int J Cardiol. 2004;94(2-3):235-240. - PubMed
  42. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621-627. - PubMed
  43. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005;24(11):1736-1740. - PubMed
  44. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229-243. - PubMed
  45. Weis M, Pehlivanli S, Meiser BM, von Schiedt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol. 2001;38(3):814-818. - PubMed
  46. Hollis IB, Reed BN, Moranville MP. Medication management of cardiac allograft vasculopathy after heart transplantation. Pharmacotherapy. 2015;35(5):489-501. - PubMed
  47. de Lorgeril M, Loire R, Guidollet J, Boissonnat P, Dureau G, Renaud S. Accelerated coronary artery disease after heart transplantation: the role of enhanced platelet aggregation and thrombosis. J Intern Med. 1993;233(4):343-350. - PubMed
  48. Peled Y, Lavee J, Raichlin E, et al. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up. Clin Transplant. 2017;31(12):1-7. - PubMed
  49. Kim M, Mehra MR, Stewart GC, et al. Early use of antiplatelet therapy and development of cardiac allograft vasculopathy: a 5 year outcomes analysis. J Heart Lung Transplant. 2016;35(4):S99. - PubMed
  50. Schroeder JS, Gao S-Z, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328(3):164-170. - PubMed
  51. Carrier M, Rivard M, Kostuk W, et al. The Canadian study of cardiac transplantation. Atherosclerosis. Investigators of the CASCADE study. Can J Cardiol. 1999;15(12):1337-1344. - PubMed
  52. Erinc K, Yamani MH, Starling RC, et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant. 2005;24(8):1033-1038. - PubMed
  53. Fearon WF, Okada K, Kobashigawa JA, et al. Angiotensin-converting enzyme inhibition early after heart transplantation. J Am Coll Cardiol. 2017;69(23):2832-2841. - PubMed
  54. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2-3):85-118. - PubMed
  55. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24(5):517-525. - PubMed
  56. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66(4):507-515. - PubMed
  57. Asleh R, Briasoulis A, Kremers WK, et al. Long-term sirolimus for primary immunosuppression in heart transplant recipients. J Am Coll Cardiol. 2018;71(6):636-650. - PubMed
  58. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14(7):1055-1070. - PubMed
  59. Arora S, Andreassen AK, Karason K, et al. Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients. Three-year results of a scandinavian randomized trial. Circ Heart Fail. 2018;11:e004050. - PubMed
  60. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110(17):2694-2700. - PubMed
  61. Kobashigawa JA, Pauly DF, Starling RC, et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail. 2013;1(5):389-399. - PubMed
  62. Viganò M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant. 2007;26(6):584-592. - PubMed
  63. Jennings DL, Lange N, Shullo M, et al. Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis. Int J Cardiol. 2018;265:71-76. - PubMed
  64. Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation. 2011;92(2):235-243. - PubMed
  65. Masetti M, Potena L, Nardozza M, et al. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant. 2013;13(5):1217-1226. - PubMed
  66. Matsuo Y, Cassar A, Yoshino S, et al. Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation. J Heart Lung Transplant. 2013;32(8):784-791. - PubMed
  67. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108(1):48-53. - PubMed
  68. Raichlin E, Bae J-H, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation. 2007;116(23):2726-2733. - PubMed
  69. Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation. 2012;125(5):708-720. - PubMed
  70. Potena L, Pellegrini C, Grigioni F, et al. Optimizing the safety profile of everolimus by delayed initiation in de novo heart transplant recipients: results of the prospective randomized study EVERHEART. Transplantation. 2018;102(3):493-501. - PubMed
  71. Lee MS, Lluri G, Finch W, Park KW. Role of Percutaneous Coronary Intervention in the Treatment of Cardiac Allograft Vasculopathy. Am J Cardiol. 2018;121(9):1051-1055. - PubMed
  72. Dasari TW, Hennebry TA, Hanna EB, Saucedo JF. Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature. Catheter Cardiovasc Interv. 2011;77(7):962-969. - PubMed
  73. Cheng R, Vanichsarn C, Patel JK, et al. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy. Catheter Cardiovasc Interv. 2017;90(1):48-55. - PubMed
  74. Luc JGY, Choi JH, Rizvi S-S, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in heart transplant recipients with coronary allograft vasculopathy: a systematic review and meta-analysis of 1,520 patients. Ann Cardiothorac Surg. 2018;7(1):19-30. - PubMed
  75. Goldraich LA, Stehlik J, Kucheryavaya AY, Edwards LB, Ross HJ. Retransplant and medical therapy for cardiac allograft vasculopathy: international society for heart and lung transplantation registry analysis. Am J Transplant. 2016;16(1):301-309. - PubMed
  76. Mehra MR. The scourge and enigmatic journey of cardiac allograft vasculopathy. J Heart Lung Transplant. 2017;36(12):1291-1293. - PubMed
  77. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782-1791. - PubMed

MeSH terms

Publication Types